Market and sector review

Global equity markets ended the month broadly unchanged from the end of August, but, under the surface, there was a wide dispersion of returns among sectors and market-cap sizes. AI-exposed sectors continued to march higher, while more cyclical and consumer-dependent sectors fell sharply, mainly because of rising energy prices and bond yields. High interest rates also hurt smaller capitalisation stocks, with the Russell 2000 Index lagging behind the S&P 500 by close to 5% in the month.

Against this backdrop, healthcare underperformed the broader market but was still the third best-performing sector, finishing behind only information technology and communication services, which the AI trade propelled higher. Within healthcare, life sciences tools and services, healthcare facilities, biotechnology and pharmaceuticals were the strongest-performing sub-industries, while healthcare supplies, equipment and services had a more challenging month.

September has forced a reappraisal of the softening-economy narrative in the US and confirmed that the tightening cycle is back. August payroll figures were strong and removed the labour market as an obstacle to hiking interest rates. Meanwhile August’s core consumer price index (CPI) ran slightly higher than expected, with gasoline prices up considerably as the Iran-driven energy shock feeds visibly into headline prices. Given this background, the Federal Reserve (Fed) duly delivered its first hike since 2023 in mid-September, a unanimous 25bps move to 3.75-4.00%, with the dot plot pointing to another this year. The more consequential move has been in bonds: the 10-year US Treasury yield broke above 5% for the first time since 2007 and the 30-year reached its highest since 2004, meaning the long end is doing much of the Fed's work.

In this context, the fact that many equity indices closed at or near all-time highs is perhaps baffling. However, the market’s leadership has been exceptionally narrow – AI earnings are still strong enough to absorb a hiking cycle and AI-linked mega-cap stocks moved higher, while everything else is quietly repricing for a higher-for-longer scenario. A durable de-escalation of the US-Iran war would seem to us to be a clear upside catalyst for equities and could see breadth extend beyond the concentrated AI-beneficiary cohort.

Company performance

The Company’s net asset value (NAV)1 declined 2.8% in September, behind its benchmark, the MSCI All Country World Daily Net Total Return Health Care Index, which was down 0.2% (both figures in sterling terms).

Positive contributors relative to the benchmark in September were Teva Pharmaceutical Industries (Teva), Agilent Technologies and Novo Nordisk (Novo)*.

Teva performed well during the month, with the company announcing positive early data for a drug in coeliac disease, providing encouraging commentary on its ability to execute on key priorities during a busy conference season, but also starting a direct listing of its shares on the New York Stock Exchange.

Like the rest of the life sciences tools and services subsector, Agilent Technologies rallied on renewed investor confidence that the industry’s end markets are improving and that AI could provide a tailwind by increasing lab activity.

Novo hosted an investor event that failed to reinject enthusiasm into the story. Some hoped the Danish giant would look at diversifying its business away from metabolic diseases but management instead reiterated its focus on obesity and diabetes. Not owning Novo helped the Company’s performance relative to the benchmark as Novo’s share price fell.

Negative contributors included Xenon Pharmaceuticals, Hansa Biopharma and Ionis Pharmaceuticals.

Xenon Pharmaceuticals disclosed it had submitted the application for its lead pipeline asset azetukalner to the FDA for focal onset seizures (or FOS, a type of epilepsy), but it also shared that it had to pause enrolment in its depression trials. Though the depression indications were not key to the thesis, the setback made some investors question the commercial implications for the FOS indication.

There was no material news concerning Hansa Biopharma, which was caught in the selloff of small-cap biotechnology stocks during the month.

Ionis Pharmaceuticals was weak after its partner Novartis announced the failure of pelacarsen, a drug being studied to reduce cardiovascular events.

Company activity

We initiated positions in Centene and AxoGen during September.

Centene is performing well across its business lines. It is on track to deliver a target profit margin of more than 5% in 2027 on its book of customers through the Affordable Care Act (ACA) Exchange. We also believe that better rates across its Medicaid2 segment should allow it to deliver strong growth in earnings per share over the next few years. Additionally, we see Centene as relatively well-positioned should the Democrats gain significant momentum in the mid-term elections, given the party has historically been supportive of access to care including the Medicaid programme.

AxoGen, a US medical device company, has the first and only US Food and Drug Administration (FDA)-licensed biologic nerve graft used to repair peripheral nerve damage. With an increase in Medicare3 outpatient reimbursement (the amount the US government health insurance programme pays for outpatient care) and a run of commercial coverage wins, we expect durable top-line growth and improving cashflow. Additionally, there is a large opportunity to expand the use of AxoGen’s technology beyond the current indications. We funded the positions, in part, by exiting Chugai Pharmaceutical.

Outlook

We believe healthcare is in a good place. By the end of September, the FDA had approved 45 novel drugs, a figure that compares very favourably with the 32 approved over the same period in 2025. Importantly, the approvals are in commercially attractive areas such as autoimmune disorders, pancreatic cancer, hypertension and obesity. The sector is also enjoying a period of positive earnings revisions and is forecast to deliver faster 2027 vs 2026 earnings growth than the broader market, a key driver of share prices rising faster than the wider market.

Last but not least, healthcare is showing leadership alongside technology from a technical perspective, with a large number of stocks recently hitting relative highs. 


*not held